Oral Pre-Exposure Prophylaxis (PrEP) for HIV Prevention in Adolescents and Young Adults.
Oral Pre-Exposure Prophylaxis (PrEP) for HIV Prevention in Adolescents and Young Adults.
复制标题
DOI：
10.1007/s40124-018-0163-x
复制
发表时间：
2018-06
影响因子：
1.9
通讯作者：
Lehmann CE
中科院分区：
文献类型：
--
作者：
Mullins TLK;Lehmann CE
回顾有关用于预防艾滋病病毒（HIV）的口服暴露前预防（PrEP）的文献，特别关注青少年。
PrEP的使用减少了男男性行为者、异性恋者和注射吸毒者中的新增HIV感染。一种抗逆转录病毒联合药物在美国被批准用于成人的PrEP。有限的数据表明PrEP在青少年中使用是安全的，尽管随着时间推移PrEP依从性下降，这表明需要专门针对青少年的依从性干预措施。与PrEP相关的安全问题包括对骨密度和肾功能的潜在负面影响，以及可能增加高风险性行为。美国公共卫生服务机构已经发布了成人使用PrEP的指南。
目前的数据表明青少年使用PrEP是安全的；然而，需要进一步研究长期使用PrEP对骨密度和肾功能的潜在影响。
To review the literature about oral pre-exposure prophylaxis (PrEP) for HIV prevention, with specific focus on adolescents. Use of PrEP reduces new HIV infections among men who have sex with men, heterosexuals, and people who inject drugs. One combination antiretroviral medication is approved for PrEP in the U.S. for adults. Limited data suggest that PrEP is safe for use in youth, although declines in adherence to PrEP over time suggest the need for adherence interventions specifically targeting youth. Safety concerns related to PrEP include potential negative impacts on bone density and renal function, as well as potential increases in riskier sexual behaviors. The U.S. Public Health Service has published guidelines for PrEP use in adults. Current data suggest that PrEP use is safe in adolescents; however, further research is needed on the potential impact of long-term PrEP use on bone density and kidney function.